Savine Therapeutics Pty Ltd is a limited by shares Australian proprietary company. Located at ACT 2601 since 2010-08-16 the company is, as the updated on 2010-08-17 ABN database shows, registered. The company has been registered for Goods & Services Tax since 2008-05-15. Known company numbers for Savine Therapeutics Pty Ltd are as follows: ACN - 128146869, Australian Business Number - 40128146869. This Australian proprietary company was previously located in NSW 2114 (from 2008-05-15 to 2010-08-16).
| Status | From | To |
|---|---|---|
| Active | 15th May 2008 | current |
| Name | From | To |
|---|---|---|
| Savine Therapeutics Pty Ltd | 15th May 2008 | current |
| Location | From | To |
|---|---|---|
| ACT 2601 | 16th August 2010 | current |
| NSW 2114 | 15th May 2008 | 16th August 2010 |
| Status | From | To |
|---|---|---|
| Registered | 15th May 2008 | current |
Advertisements
International Patent Classification:
| IPC Mark: | C07K 14/16 |
| Section code: | C - chemistrymetallurgy |
| Class code: | 7 - organic chemistry |
| Subclass code: | K - peptides (peptides containing -lactam rings c07d; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, c07d; ergot alkaloids of the cyclic peptide type c07d0519020000; genetic engineering processes for obtaining peptides c12n0015000000) |
| Main group code: | 14 - peptides having more than 20 amino acids; gastrins; somatostatins; melanotropins; derivatives thereof |
| Subgroup code: | 16 - hiv-1 |
IP Australia process information:
| Expiry date: | 25th May 2021 |
General information:
| Patent status: |
Lapsed Either the application has not been accepted by 21 months after the first examination report (or 12 months after the Raising the Bar Act) or some other deadline in the prosecution process has not been completed in time, for example IP Australia has issued a direction to file a request for examination and the applicant has not done so in the required period (2 months). |
| Patent type: | NPE |
International Patent Classification:
| IPC Mark: | C12N 15/34 |
| Section code: | C - chemistrymetallurgy |
| Class code: | 12 - biochemistry; beer; spirits; wine; vinegar; microbiology; enzymology; mutation or genetic engineering |
| Subclass code: | N - micro-organisms or enzymes; compositions thereof (biocides, pest repellants or attractants, or plant growth regulators containing micro-organisms, viruses, microbial fungi, enzymes, fermentates, or substances produced by, or extracted from, micro-organisms or animal material a01n0063000000; medicinal preparations a61k; fertilisers c05f); propagating, preserving, or maintaining micro-organisms; mutation or genetic engineering; culture media (microbiological testing media c12q0001000000) |
| Main group code: | 15 - mutation or genetic engineering; dna or rna concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; use of hosts therefor (mutants or genetically engineered micro-organisms c12n0001000000, c12n0005000000, c12n0007000000; new plants a01h; plant reproduction by tissue culture techniques a01h0004000000; new animals a01k0067000000; use of medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases, gene therapy a61k0048000000; peptides in general c07k) |
| Subgroup code: | 34 - proteins from dna viruses |
IP Australia process information:
| Expiry date: | 6th December 2026 |
Contains public sector information licensed under the Creative Commons Attribution 3.0 Australia licence. Material on this website was obtained from publicly-accessible databases and is attributed to ©Commonwealth of Australia 2024 (http://data.gov.au, http://acnc.gov.au/ and http://abr.business.gov.au/), ©Intellectual Property Government Open Data 2024, ©ASIC - Company Register. While we try to make the information as precise and up-to-date as possible, we are aware the datasets are not always error-free. Aubiz.net will not take responsibility for any errors in the databases. The material provided should be treated as a starting point of more in-depth research, not as fact.